Drugs / Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein
Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05426369 | Jun 2022 → Jul 2025 overdue | thrombocytopenia | Sichuan Clover Biopharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05426369 ↗ |
| Modality | Protein / enzyme biologic | “TPO Mimetic Peptide Fusion Protein” NCT05426369 ↗ |
| Route | Subcutaneous | “single and multiple subcutaneous injections of SCB-219M for CIT” NCT05426369 ↗ |